Drug interactions
Rosiglitazone + Selexipag
Severity: Minor
Rosiglitazone and Selexipag: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Rosiglitazone is a weak-to-moderate CYP2C8 inhibitor, and CYP2C8 is involved in converting selexipag to its active metabolite. Exposure to selexipag may rise slightly, which could increase prostacyclin-related adverse effects such as headache, jaw pain, nausea and diarrhea.
What this interaction means in plain words
Rosiglitazone and Selexipag have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Rosiglitazone belongs to Endocrine; Selexipag belongs to Cardiovascular.
Why it happens
Inhibition of CYP2C8-mediated metabolism of selexipag and its active metabolite by rosiglitazone.
What to do
Watch for prostacyclin-type adverse effects when starting rosiglitazone in a patient taking selexipag. Selexipag dosing should be reduced to once daily only if a strong CYP2C8 inhibitor is added, which is not the case with rosiglitazone.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Rosiglitazone and Selexipag, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Rosiglitazone
- Insulin aspart protamine / insulin aspart + Rosiglitazone Major
- Insulin aspart-insulin aspart protamine + Rosiglitazone Major
- Insulin aspart + Rosiglitazone Major
- Insulin degludec / insulin aspart + Rosiglitazone Major
- Insulin degludec-insulin aspart + Rosiglitazone Major
- Insulin degludec-liraglutide + Rosiglitazone Major
Other interactions of Selexipag
- Gemfibrozil + Selexipag Contraindicated
- Abiraterone + Selexipag Moderate
- Apalutamide + Selexipag Moderate
- Carbamazepine + Selexipag Moderate
- Clopidogrel + Selexipag Moderate
- Cyclosporin + Selexipag Moderate
Frequently asked questions
Can I take Rosiglitazone with Selexipag?
MediHelp rates the interaction as minor. Rosiglitazone and Selexipag have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Rosiglitazone is a weak-to-moderate CYP2C8 inhibitor, and CYP2C8 is involved in converting selexipag to its active metabolite. Exposure to selexipag may rise slightly, which could increase prostacyclin-related adverse effects such as headache, jaw pain, nausea and diarrhea.
How serious is the interaction between Rosiglitazone and Selexipag?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Watch for prostacyclin-type adverse effects when starting rosiglitazone in a patient taking selexipag. Selexipag dosing should be reduced to once daily only if a strong CYP2C8 inhibitor is added, which is not the case with rosiglitazone.
What other medicines interact with Rosiglitazone?
MediHelp also lists interactions of Rosiglitazone with, for example, Insulin aspart protamine / insulin aspart, Insulin aspart-insulin aspart protamine, Insulin aspart. The full list is on the Rosiglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
